tetano
Editor, Senior Moderator
J Infect Dis
. 2024 Jul 25;230(1):e17-e29.
doi: 10.1093/infdis/jiad590. Delayed Mucosal Antiviral Responses Despite Robust Peripheral Inflammation in Fatal COVID-19
Jasmin K Sidhu[SUP] 1 [/SUP], Matthew K Siggins[SUP] 1 [/SUP], Felicity Liew[SUP] 1 [/SUP], Clark D Russell[SUP] 2 [/SUP], Ashley S S Uruchurtu[SUP] 1 [/SUP], Christopher Davis[SUP] 3 [/SUP], Lance Turtle[SUP] 4 5 [/SUP], Shona C Moore[SUP] 4 [/SUP], Hayley E Hardwick[SUP] 4 [/SUP], Wilna Oosthuyzen[SUP] 6 [/SUP], Emma C Thomson[SUP] 3 7 [/SUP], Malcolm G Semple[SUP] 8 9 [/SUP], J Kenneth Baillie[SUP] 6 10 [/SUP], Peter J M Openshaw[SUP] 1 [/SUP], Ryan S Thwaites[SUP] 1 [/SUP]; ISARIC4C investigators
Collaborators, Affiliations
Background: While inflammatory and immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in peripheral blood are extensively described, responses at the upper respiratory mucosal site of initial infection are relatively poorly defined. We sought to identify mucosal cytokine/chemokine signatures that distinguished coronavirus disease 2019 (COVID-19) severity categories, and relate these to disease progression and peripheral inflammation.
Methods: We measured 35 cytokines and chemokines in nasal samples from 274 patients hospitalized with COVID-19. Analysis considered the timing of sampling during disease, as either the early (0-5 days after symptom onset) or late (6-20 days after symptom onset) phase.
Results: Patients that survived severe COVID-19 showed interferon (IFN)-dominated mucosal immune responses (IFN-γ, CXCL10, and CXCL13) early in infection. These early mucosal responses were absent in patients who would progress to fatal disease despite equivalent SARS-CoV-2 viral load. Mucosal inflammation in later disease was dominated by interleukin 2 (IL-2), IL-10, IFN-γ, and IL-12p70, which scaled with severity but did not differentiate patients who would survive or succumb to disease. Cytokines and chemokines in the mucosa showed distinctions from responses evident in the peripheral blood, particularly during fatal disease.
Conclusions: Defective early mucosal antiviral responses anticipate fatal COVID-19 but are not associated with viral load. Early mucosal immune responses may define the trajectory of severe COVID-19.
Keywords: COVID-19; SARS-CoV-2; airway; chemokine; cytokine; lung; mucosa; nose; virus.
. 2024 Jul 25;230(1):e17-e29.
doi: 10.1093/infdis/jiad590. Delayed Mucosal Antiviral Responses Despite Robust Peripheral Inflammation in Fatal COVID-19
Jasmin K Sidhu[SUP] 1 [/SUP], Matthew K Siggins[SUP] 1 [/SUP], Felicity Liew[SUP] 1 [/SUP], Clark D Russell[SUP] 2 [/SUP], Ashley S S Uruchurtu[SUP] 1 [/SUP], Christopher Davis[SUP] 3 [/SUP], Lance Turtle[SUP] 4 5 [/SUP], Shona C Moore[SUP] 4 [/SUP], Hayley E Hardwick[SUP] 4 [/SUP], Wilna Oosthuyzen[SUP] 6 [/SUP], Emma C Thomson[SUP] 3 7 [/SUP], Malcolm G Semple[SUP] 8 9 [/SUP], J Kenneth Baillie[SUP] 6 10 [/SUP], Peter J M Openshaw[SUP] 1 [/SUP], Ryan S Thwaites[SUP] 1 [/SUP]; ISARIC4C investigators
Collaborators, Affiliations
- PMID: 39052740
- DOI: 10.1093/infdis/jiad590
Background: While inflammatory and immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in peripheral blood are extensively described, responses at the upper respiratory mucosal site of initial infection are relatively poorly defined. We sought to identify mucosal cytokine/chemokine signatures that distinguished coronavirus disease 2019 (COVID-19) severity categories, and relate these to disease progression and peripheral inflammation.
Methods: We measured 35 cytokines and chemokines in nasal samples from 274 patients hospitalized with COVID-19. Analysis considered the timing of sampling during disease, as either the early (0-5 days after symptom onset) or late (6-20 days after symptom onset) phase.
Results: Patients that survived severe COVID-19 showed interferon (IFN)-dominated mucosal immune responses (IFN-γ, CXCL10, and CXCL13) early in infection. These early mucosal responses were absent in patients who would progress to fatal disease despite equivalent SARS-CoV-2 viral load. Mucosal inflammation in later disease was dominated by interleukin 2 (IL-2), IL-10, IFN-γ, and IL-12p70, which scaled with severity but did not differentiate patients who would survive or succumb to disease. Cytokines and chemokines in the mucosa showed distinctions from responses evident in the peripheral blood, particularly during fatal disease.
Conclusions: Defective early mucosal antiviral responses anticipate fatal COVID-19 but are not associated with viral load. Early mucosal immune responses may define the trajectory of severe COVID-19.
Keywords: COVID-19; SARS-CoV-2; airway; chemokine; cytokine; lung; mucosa; nose; virus.